Natera, Inc. Q3 2026 Earnings Conference Call - NATERA INC

Financial Performance:

• Q3 2026 revenue reached $794 million, a 34% year-over-year increase, rising to over 40% when excluding true-ups; true-ups decreased to $32 million from $52 million in Q2.
• Gross margin held at approximately 65% sequentially; excluding true-ups, the adjusted gross margin was 63.2%, an increase of 140 basis points from Q2.
• Total test volume grew to approximately 1.1 million units (up 22% YoY), with Clinical MRD (ctDNA) units reaching 316,000 (up 56% YoY), representing the second consecutive quarter with sequential growth exceeding 30,000 units.
• The company generated cash and narrowed losses significantly while maintaining aggressive investment levels.
• Signatera ASPs increased to approximately $1,290, with a long-term target to exceed $2,000 as coverage expands.

Guidance and Future Outlook:

• Raised full-year 2026 revenue guidance to $3.005 billion–$3.035 billion (midpoint), representing an increase of $140 million from the previous outlook.
• Established a long-term target to double revenues to $6 billion by 2029, driven primarily by existing MRD, pharma/data services, and international expansion rather than early detection screening.
• 2027 guidance includes a projected 10%–12% increase in OPEX (up to $1.3 billion at the top end) to support scaling of pharma/data services and clinical trial investments.
• Gross margin for 2027 is expected to remain in the 64%–66% range, with a trajectory toward 70%+ margins long-term as ASPs rise and COGS efficiencies are realized.
• Management remains confident in achieving profitability through growth, leveraging the "cash library" milestone hit in 2024 as a precedent.

Business Segments and Product Lines:

• Oncology (Signatera/Latitude MRD): Core growth driver; volumes accelerating across tumor types (colorectal, breast, bladder, lung) with increasing repeat testing rates.
• Signatera Genome: New platform integrating phased and structural variants launched with an LOD of 95% < 1 part per million, selected for global Phase III trials (e.g., AFT-70 Navigate).
• Women's Health: Mid-to-high single-digit growth driven by "Fetal Focus" product and integrated deep sequencing features; market consolidation (LabCorp/Mayo) viewed as a positive signal for sector demand.
• Organ Health: Volumes grew nearly 40% YoY, supported by Medicare coverage for surveillance (announced July 2026, effective August 30).
• Pharma & Data Services: Revenue surged ~70% in the first three quarters of 2026 versus all of 2025; major growth driven by MRD-guided clinical trials and data licensing assets.
• International: On track to launch Signatera in Japan for colorectal cancer and muscle-invasive bladder cancer; pricing negotiations with the Japanese Ministry of Health are underway.

Market and Competitive Landscape:

• Medicare Coverage: Secured coverage for Signatera in early-stage hepatocellular carcinoma (HCC), marking a significant win; additional MolDx submissions are in progress for bladder, lung, and other cancers.
• Competitive Position: Management welcomes competition, citing a "flywheel" effect where physician adoption in one tumor type drives adoption in others; no change in competitive dynamics despite new entrants in prenatal testing.
• Market Trends: MRD is shifting from prognostic to predictive, changing treatment decisions (e.g., de-escalation in colon and bladder cancer trials).
• Global Expansion: Japan launch expected to be rapid due to high colorectal cancer incidence and existing clinician familiarity from prior trials.

Risks and Challenges:

• COGS Pressures: Short-term gross margin dilution anticipated from new product launches (Signatera Genome, Fetal Focus), though 18–24 month roadmaps exist to reduce costs.
• Clinical Trial Timelines: Major practice-changing trials (e.g., SIGNAL, AFT-70) will not read out until several years later; 2029 revenue target does not rely on early screening data readouts.
• Reimbursement Uncertainty: Future growth depends on successful MolDx submissions and guideline inclusions; pricing outcomes in international markets (Japan) remain unconfirmed.
• Operational Scaling: Accelerating pharma/data demand requires significant upfront investment in commercial teams and operations, impacting short-term OPEX.

Management Commentary and Tone:

• Leadership Transition: Founder and long-serving CEO Steve Chapman stepped down to transition to Solomon Moscovich (current COO), whom he hired in 2011; Chapman remains as a consultant and board advisor.
• Tone: Highly confident and "execution-focused," with management emphasizing that the $6 billion target is achievable through steady commercial execution rather than "miracles."
• Strategic Continuity: New CEO Solomon Moscovich stated no radical strategic changes would be made, adhering to the existing formula of generating practice-changing data and maintaining product quality.
• Mission: Reiterated commitment to building an enduring healthcare company focused on earlier interventions and reducing unnecessary treatment.

Analyst Questions and Answers:

• Priorities & Strategy: Moscovich confirmed focus remains on customer service, data generation, and product trust; no tactical shifts expected.
• $6B Target Composition: Revenue composition will rely on existing MRD growth (volumes + ASPs) and pharma/data services (targeting several hundred million by 2029); early detection screening will be a minor contributor in 2028–2029.
• HCC & MolDx Pipeline: HCC coverage is a major milestone; 9–10 additional MolDx submissions are in flight, which could significantly boost ASPs.
• Gross Margin Trajectory: 70%+ long-term margins are expected; immediate term involves balancing new product COGS against eventual ASP increases and cost-reduction projects.
• Japan Launch: Expected to be as fast or faster than US adoption due to high disease incidence and established clinician relationships; pricing anticipated to be accretive to US ASPs.
• Competitive Landscape: Consolidation in prenatal testing viewed as market validation; management remains focused on differentiating via superior analytical performance (phased variants) and clinical evidence.
• OpEx 2027: Projected 10–12% growth to fund ECD (Early Cancer Detection) and MRD clinical trials, maintaining a "foot on the gas" approach.

Other Key Points:

• Clinical Evidence: Significant data presented at ESMO and Nature Medicine showing Signatera changing treatment plans (e.g., 1 in 3 patients in Sagittarius trial had plans changed; 91% 24-month EFS in Volga study).
• FIND Study: Fully enrolled with 30,000 patients for PMA cohort; FDA granted Breakthrough Device Designation for multi-cancer early detection.
• Asset Value: Natera possesses a unique data asset with over 500,000 tested patients, multiple time points, and matched genomic data, driving pharma interest.
• Cash Flow: Continued generation of free cash flow despite heavy reinvestment in future growth vectors.